Teva Pharmaceutical Industries Ltd (NYSE:TEVA) – Equities researchers at Jefferies Group issued their Q1 2018 EPS estimates for shares of Teva Pharmaceutical Industries in a research note issued to investors on Tuesday. Jefferies Group analyst D. Steinberg forecasts that the company will earn $0.58 per share for the quarter. Jefferies Group currently has a “Hold” rating and a $19.00 target price on the stock. Jefferies Group also issued estimates for Teva Pharmaceutical Industries’ Q2 2018 earnings at $0.52 EPS, Q3 2018 earnings at $0.49 EPS and Q4 2018 earnings at $0.51 EPS.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The business had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter last year, the firm earned $1.38 earnings per share. The company’s revenue for the quarter was down 15.9% compared to the same quarter last year.
Shares of Teva Pharmaceutical Industries stock opened at $16.91 on Thursday. The company has a quick ratio of 0.58, a current ratio of 0.86 and a debt-to-equity ratio of 1.91. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $33.82. The stock has a market capitalization of $17,897.04, a PE ratio of -1.04, a PEG ratio of 1.53 and a beta of 0.65.
In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 5,050 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $19.68, for a total transaction of $99,384.00. Following the transaction, the executive vice president now owns 44,517 shares of the company’s stock, valued at approximately $876,094.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last ninety days, insiders have sold 10,734 shares of company stock worth $204,795. 7.10% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the company. Calton & Associates Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $108,000. Fieldpoint Private Securities LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $171,000. Global Financial Private Capital LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $193,000. Wetherby Asset Management Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $197,000. Finally, Sigma Planning Corp acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $214,000. Institutional investors and hedge funds own 58.19% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.